‘Not New Anymore’: EMA Moves Biosimilars Closer To Generic-Drug Review Model
As confidence in biosimilars grows, the European Medicines Agency is testing whether less complex marketing applications for such products can be reviewed with fewer regulatory resources, potentially freeing up assessment teams for other medicines.
Generics Bulletin - July 27, 2026

Dr Reddy’s Semaglutide Woes Ripple Through Partners, CEO Vows Comeback
With "tens of partners" globally, Dr Reddy’s semaglutide supply challenges could potentially have a wider impact if the firm isn’t back in the market by November as anticipated. Partner Aspen has already flagged delays, and a Sandoz Canada supply commitment also hangs on a timely restart.
Generics Bulletin - July 27, 2026

Zevra Europe Entry Plans For Neimann-Pick Drug Put On Hold
The US firm is appealing a CHMP negative opinion on its Niemann-Pick disease type C therapy Meplyffa, stalling having hit a stumbling block in its efforts to enter a market which is larger than the US, where the ultra-rare lysosomal storage disorder drug is already approved.
Scrip - July 27, 2026

Acute Care AI Pioneer Viz.ai Takes First Step Into Chronic Brain Disease
Viz.ai is expanding beyond acute care into neurodegenerative disease, partnering with Cortechs.ai to bring quantitative brain MRI analysis into its 2,000-hospital network — with MS as the entry point and broader ambitions to follow.
Medtech Insight - July 27, 2026

Niagen Bioscience Adds External Research Chief
Abhijit Kale oversees firm’s network of academic and clinical research collaborations while helping shape scientific research strategy.
HBW Insight - July 27, 2026

The Eyes Have It! FDA Finally Approves Outlook’s Ophthalmic Bevacizumab
Outlook Therapeutics has set out initial launch plans for its Lytenava ophthalmic bevacizumab product after finally winning approval from the US FDA.
Generics Bulletin - July 27, 2026

AstraZeneca Trial Wobbles Continue With Claudin 18.2 ADC Hit and Miss
A split CLARITY-Gastric01 readout gives AstraZeneca the first survival win for a CLDN18.2 ADC, but the PFS miss leaves room for rivals closing in on the same indication.
Scrip - July 27, 2026

Par Seizes First-Mover Advantage In Janumet XR Generics
Par Health has launched the first and currently only US Food and Drug Administration-approved generic version of Merck & Co’s Janumet XR (sitagliptin/metformin hydrochloride) extended-release tablets in the US, opening generic competition for the extended-release diabetes therapy shortly after agree
Generics Bulletin - July 27, 2026

Argenx To Buy Forte Biosciences For $2.2bn, Adds Clinical-Stage CD122 Autoimmune Asset
Argenx's $2.2bn acquisition of Forte Biosciences adds anti-CD122 antibody FB102 to its immunology pipeline, with the upcoming Phase II celiac disease data the first test of the asset's potential beyond Vyvgart.
Scrip - July 27, 2026

The Generics Bulletin Top 50, Part One: The Big Three No More
In the first part of this year’s Generics Bulletin Top 50, we find out which one of the traditional big three off-patent companies has been pushed off the winner’s podium this year – and how far they have fallen down the top ten.
Generics Bulletin - July 27, 2026

CareDx CEO On Precision Diagnostics Pivot, Oncology Expansion
CareDx CEO John Hanna details the twin deals — a $171.2m lab products divestiture and the up-to-$260m Naveris buy — that recast the transplant-diagnostics firm as a molecular diagnostics company betting on reimbursed, repeat-tested oncology niches led by the Medicare-covered NavDx.
Medtech Insight - July 27, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Novo Nordisk sues Lilly in obesity battle; Trump takes new tariff action on generics; Novartis CEO praises Japan, blasts Germany on pricing; could pharma have a rare earth moment?; and European biotech at a crossroads.
Scrip - July 27, 2026